X
Total 959151 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Radionuclide Positron Fraction | The radionuclide positron fraction (fraction of decays that are by positron emission) that was used in the correction of this image. | ILX:0109623 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Radionuclide Total Dose | The radiopharmaceutical dose administered to the patient at the Radiopharmaceutical Start Time (0018,1072). | ILX:0109624 | 5 | FDI Lab - SciCrunch.org | 08/28/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | troy sincomb |
| Radiopharmaceutical | Name of the radiopharmaceutical. | ILX:0109625 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Radiopharmaceutical Code Sequence | Sequence that identifies the radiopharmaceutical. | ILX:0109626 | 6 | FDI Lab - SciCrunch.org | 08/28/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | troy sincomb |
| Radiopharmaceutical Information Sequence | Sequence of Items that describe isotope information. | ILX:0109627 | 5 | FDI Lab - SciCrunch.org | 08/28/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | troy sincomb |
| Radiopharmaceutical Route | Route of administration. | ILX:0109628 | 7 | FDI Lab - SciCrunch.org | 08/28/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | troy sincomb |
| Radiopharmaceutical Specific Activity | The activity per unit mass of the radiopharmaceutical, in Bq/micromole, at the Radiopharmaceutical Start DateTime (0018,1078). | ILX:0109629 | 5 | FDI Lab - SciCrunch.org | 08/28/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | troy sincomb |
| Radiopharmaceutical Start Time | Time of start of administration. The actual time of radiopharmaceutical administration to the patient for imaging purposes, using the same time base as Series Time (0008,0031). The use of this Attribute is deprecated in favor of Radiopharmaceutical Start DateTime (0018,1078). The use of a time alone can cause confusion when the procedure spans midnight. | ILX:0109630 | 5 | FDI Lab - SciCrunch.org | 08/28/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | troy sincomb |
| Radiopharmaceutical Stop Time | Time of end of administration. The actual ending time of radiopharmaceutical administration to the patient for imaging purposes, using the same time base as Series Time (0008,0031). The use of this Attribute is deprecated in favor of Radiopharmaceutical Stop DateTime (0018,1079). The use of a time alone can cause confusion when the procedure spans midnight. | ILX:0109631 | 8 | FDI Lab - SciCrunch.org | 08/28/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | troy sincomb |
| Radiopharmaceutical Volume | Volume of injection in cubic cm. | ILX:0109632 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Radius | ILX:0109633 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex | |
| Radius of Circular Collimator | Required if Collimator Shape (0018,1700) is CIRCULAR. Radius of the circular collimator expressed as effective number of pixels along the row direction. | ILX:0109634 | 5 | FDI Lab - SciCrunch.org | 08/28/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | troy sincomb |
| Raised | A thick colony that appears above the medium surface with terraced edges. | ILX:0109635 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Raloxifene | A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue. (PubChem) Pharmacology: Raloxifene, a selective estrogen receptor modulator (SERM) of the benzothiophene class, is similar to tamoxifen in that it produces estrogen-like effects on bone and lipid metabolism, while antagonizing the effects of estrogen on mammary tissue. Raloxifene decreases bone resorption, increases bone mineral density (BMD) and decreases incidence of fractures. Raloxifene is used in the prevention of postmenopausal osteoporosis and breast cancer. Mechanism of action: Raloxifene binds to estrogen receptors, resulting in differential expression of multiple estrogen-regulated genes in different tissues. Raloxifene produces estrogen-like effects on bone, reducing resorption of bone and increasing bone mineral density in postmenopausal women. Raloxifene also antagonizes the effects of estrogen on mammary tissue and blocks uterotrophic responses to estrogen. Drug type: Approved. Investigational. Small Molecule. Drug category: Antihypocalcemic Agents. Bone Density Conservation Agents. Estrogen Antagonists. Osteoporosis Prophylactic. Selective Estrogen Receptor Modulators | ILX:0109636 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Raltitrexed | Raltitrexed (brand name Tomudex) is a chemotherapy drug manufactured AstraZeneca Company, is an antimetabolite used in chemotherapy. It is an inhibitor of thymidylate synthase. Pharmacology: Raltitrexed belongs to a group of medicines known as antimetabolites. It is used to treat cancer of the colon and rectum. It may also be used to treat other kinds of cancer, as determined by your doctor. Raltitrexed blocks an enzyme needed by the cell to live. This interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal body cells may also be affected by raltitrexed, other effects will also occur. Some of these may be serious and must be reported to your doctor. Other effects, like hair loss, may not be serious but may cause concern. Mechanism of action: Raltitrexed is an antineoplastic Agents and folic acid antagonists. Raltitrexed inhibits thymidylate synthase (TS) leading to DNA fragmentation and cell death. It is transported into cells via a reduced folate carrier. Inside the cell Raltitrexed is extensively polyglutamated, which enhances thymidylate synthase inhibitory power and duration, resulting into increase of antitumor activity. Drug type: Approved. Investigational. Small Molecule. Drug category: Antimetabolites. Antimetabolites, Antineoplastic. Antineoplastic Agents. Enzyme Inhibitors. Folic Acid Antagonists | ILX:0109637 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Ramelteon | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. Pharmacology: Ramelton is the first selective melatonin agonist. It works by mimicing melatonin (MT), a naturally occuring hormone that is produced during the sleep period. It has a high affinity for the MT1 and MT2 receptor. The MT1 and MT2 receptors are located in the brain's suprachiasmatic nuclei (SCN). The SCN is known as the body's "master clock" because it regulates the 24-hour sleep-wake cycle. Ramelton has an active metabolite that is less potent but circulates in higher concentrations than the parent compound. The metabolite also has weak affinity for the 5HT2b receptor. Mechanism of action: Ramelton is a melatonin receptor agonist with both high affinity for melatonin MT1 and MT2 receptors and selectivity over the MT3 receptor. Ramelteon demonstrates full agonist activity in vitro in cells expressing human MT1 or MT2 receptors, and high selectivity for human MT 1 and MT2 receptors compared to the MT3 receptor. Drug type: Approved. Investigational. Small Molecule. Drug category: Hypnotics and Sedatives | ILX:0109638 | 4 | FDI Lab - SciCrunch.org | 08/24/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | troy sincomb |
| Ramipril | A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat. (PubChem) Pharmacology: Ramipril is an angiotensin-converting enzyme (ACE) inhibitor similar to benazepril, fosinopril, and quinapril. An inactive prodrug, ramipril is converted to ramiprilat in the liver and is used to treat hypertension and heart failure, to reduce proteinuria and renal disease in patients with nephropathies, and to prevent stroke, myocardial infarction, and cardiac death in high-risk patients. Mechanism of action: Ramiprilat, the active metabolite, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and an increase in plasma renin. Ramiprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin. Drug type: Approved. Small Molecule. Drug category: Angiotensin-converting Enzyme Inhibitors. Antihypertensive Agents | ILX:0109639 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Rana | ILX:0109640 | 5 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex | |
| Rana pipiens | ILX:0109641 | 5 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex | |
| Randoms Correction Method | Type of randoms correction processing. | ILX:0109642 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
About
The SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
Contact Us
FAIR Data Informatics Lab
University of California, San Diego
9500 Gilman Drive, Mail Code 0608
La Jolla, CA 92093-0608
United States
info 
scicrunch.org
scicrunch.org
X